Literature DB >> 3049478

[Malignant neoplasms of the lip, mouth, pharynx, nose, ear and larynx. A descriptive-epidemiologic study].

G Neumann.   

Abstract

Between 1952 and 1986 the mortality from malignant tumours of the head and neck in the German Federal Republic shows a varying picture: a decline of cancer of the lip, equivocal rates for cancer of the nose and ear, increases for cancer of the tongue and of the larynx, a marked increase for cancer of the floor of the mouth and of the hypopharynx, a lesser increase for cancer of the tonsillar area and other parts of the mouth, but almost no increase for cancer of the salivary glands. The trends are similar for males and females, but the male:female ratio increased during the observation period. The increase of mortality begins in the middle age group. Based on the data of the cancer registry of the Saarland it can be estimated that on average the incidence is twice as high as mortality. In general the trend is similar both in incidence and mortality (but not the degree of the trend). Multiple malignancies of the head and neck are observed more often than expected and patients should be followed up carefully. Combined clinical-epidemiological studies are needed.

Entities:  

Mesh:

Year:  1988        PMID: 3049478

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  3 in total

1.  Mortality from cancer of the head and neck, lung and esophagus in eastern Austria between 1960 and 1989.

Authors:  H Swoboda; H P Friedl
Journal:  Eur Arch Otorhinolaryngol       Date:  1994       Impact factor: 2.503

2.  Tobacco-related cancer in relation to prevalence of drinking and smoking in eastern Austria.

Authors:  H Swoboda; H P Friedl
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

3.  Incidence and survival trends of lip, intra-oral cavity and tongue base cancers in south-east England.

Authors:  O Olaleye; U Ekrikpo; O Lyne; J Wiseberg
Journal:  Ann R Coll Surg Engl       Date:  2015-04       Impact factor: 1.891

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.